On Monday September 26, the Department of Justice announced a settlement resolving a lawsuit filed by former employee Michael Bawduniak (the “Plaintiff”) against Biogen Inc. (the “Company”) under the qui tam provisions of the federal False Claims Act.[1]
The Plaintiff’s lawsuit[2] alleged that the Company paid kickbacks to healthcare providers (HCPs) to induce them to prescribe the Company’s multiple sclerosis (MS) drugs from Jan. 1, 2009, through March 18, 2014. These drugs included Avonex (interferon beta-1a), which had been on the market for at least a decade, and Tysabri (natalizumab), which had been pulled off of…
